HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Roquinimex (Linomide) vs placebo in AML after autologous bone marrow transplantation.

Abstract
Roquinimex, Linomide, a quinoline derivative with pleiotropic immunomodulatory activity, has previously been shown to enhance natural killer (NK) cell number and activity after ABMT in patients with AML. In this study 278 AML patients in remission were randomized to receive Roquinimex 0.2 mg/kg body weight or placebo twice weekly for 2 years following ABMT. Out of 139 patients in each group, 109 Roquinimex patients and 108 placebo patients were in their first CR. Median age at inclusion was 41 years for Roquinimex patients and 39 years for placebo patients. Twelve patients in each group had their marrow purged prior to reinfusion. Relapse and death were study endpoints. Surviving patients were followed for 2.6 to 6. 9 years. The total number of relapses was 60 in the Roquinimex group and 63 in the placebo group (not significant). Leukemia-free and overall survivals were similar in the two groups. Recovery of platelet counts was significantly delayed in the Roquinimex group as compared to placebo. No other significant differences regarding toxicity parameters were recorded. In conclusion, previous findings on NK cells could not be confirmed and the study showed no benefit for Roquinimex over placebo regarding relapse or survival following ABMT for AML in remission.
AuthorsB Simonsson, T Tötterman, P Hokland, F Lauria, A M Carella, M N Fernandez, C Rozman, A Ferrant, T de Witte, A R Zander, K Meier, F Hansson, B I Nilsson
JournalBone marrow transplantation (Bone Marrow Transplant) Vol. 25 Issue 11 Pg. 1121-7 (Jun 2000) ISSN: 0268-3369 [Print] England
PMID10849523 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial)
Chemical References
  • Angiogenesis Inhibitors
  • Hydroxyquinolines
  • Placebos
  • roquinimex
Topics
  • Adolescent
  • Adult
  • Aged
  • Angiogenesis Inhibitors (adverse effects, therapeutic use)
  • Bone Marrow Purging
  • Bone Marrow Transplantation (adverse effects)
  • Child
  • Combined Modality Therapy
  • Disease-Free Survival
  • Female
  • Follow-Up Studies
  • Humans
  • Hydroxyquinolines (adverse effects, therapeutic use)
  • Killer Cells, Natural (immunology)
  • Leukemia, Myeloid, Acute (mortality, therapy)
  • Male
  • Middle Aged
  • Placebos
  • Recurrence
  • Survival Rate
  • Time Factors
  • Transplantation, Autologous

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: